Autonomix to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024
10 Giugno 2024 - 2:00PM
– Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced it will
release preliminary results from the first five “lead-in” patients
in the Company’s ongoing proof-of-concept (PoC) human clinical
trial evaluating the safety and effectiveness of delivering
transvascular energy to ablate relevant problematic nerves and
mitigate pain in patients with pancreatic cancer pain on Tuesday,
June 18, 2024.
Autonomix management will host a webcast
presentation for investors, analysts, and other interested parties
on Tuesday, June 18, 2024 at 8:30 a.m. ET to discuss the
preliminary results. Interested participants may register for the
event here. The live webcast will be accessible on the Events page
of the Investors section of the Autonomix website, autonomix.com,
and will be archived for 90 days.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing technology for
pancreatic cancer pain, a condition that causes debilitating pain
and is without an effective solution. Our technology constitutes a
platform to address dozens of indications, including cardiology,
hypertension and chronic pain management, across a wide disease
spectrum.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Forward looking statements in this press release
include, without limitation, the potential of the technology to
treat pain associated with pancreatic cancer, to successfully
enroll patients within the specific timeframe, and to complete its
clinical study in pancreatic cancer pain. Such forward-looking
statements can be identified by the use of words such as “should,”
“might,” “may,” “intends,” “anticipates,” “believes,” “estimates,”
“projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the
expectations reflected in these forward-looking statements are
based on reasonable assumptions, there are a number of risks and
uncertainties that could cause actual results to differ materially
from such forward-looking statements. You are urged to carefully
review and consider any cautionary statements and other
disclosures, including the statements made under the heading “Risk
Factors” and elsewhere in the Annual Report on Form 10-K filed with
the U.S. Securities and Exchange Commission (“SEC”) on May 31,
2024. Forward-looking statements speak only as of the date of the
document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media Contact
JTC Team, LLCJenene Thomas
833-475-8247autonomix@jtcir.com
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Dic 2023 a Dic 2024